Literature DB >> 12067231

Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis.

Ralph W Kuncl1, Masako M Bilak, Stephan R Bilak, Andrea M Corse, Walter Royal, S Patricia Becerra.   

Abstract

Pigment epithelium-derived factor (PEDF), a recently defined retinal trophic factor and anti-angiogenic factor for the eye, is also present in the CNS and is a motor neuron protectant. We asked whether PEDF levels in CSF are altered in patients with amyotrophic lateral sclerosis (ALS). Pigment epithelium-derived factor protein was detected by quantitative western blot analysis with a PEDF-specific antiserum. Levels of PEDF in CSF, expressed as a ratio to total CSF protein, were significantly elevated 3.4-fold in 15 patients with ALS compared with neurologic disease controls (p < 0.0003). This increase does not seem likely to reflect up-regulation of PEDF synthesis in muscle in response to denervation, as CSF PEDF was not elevated in severe denervating diseases other than ALS. Nor does the increase represent some non-specific release in neurodegeneration, as CSF PEDF was not elevated in other neurodegenerative diseases. While the mechanism of this presumably reactive increase is not known, the distinctive, surprisingly elevated level of PEDF in the CSF may be an autoprotective reaction in ALS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067231     DOI: 10.1046/j.1471-4159.2002.00813.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

1.  Pigment epithelium-derived factor (PEDF) protects cortical neurons in vitro from oxidant injury by activation of extracellular signal-regulated kinase (ERK) 1/2 and induction of Bcl-2.

Authors:  A Sanchez; D Tripathy; X Yin; J Luo; J Martinez; P Grammas
Journal:  Neurosci Res       Date:  2011-09-17       Impact factor: 3.304

2.  Assays for the antiangiogenic and neurotrophic serpin pigment epithelium-derived factor.

Authors:  Preeti Subramanian; Susan E Crawford; S Patricia Becerra
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

Review 3.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

4.  Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis.

Authors:  Hua Yang; Hans E Grossniklaus
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

5.  A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse.

Authors:  Claudia M C Batista; Tod E Kippin; Sandrine Willaime-Morawek; Marília Kimie Shimabukuro; Wado Akamatsu; Derek van der Kooy
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

Review 6.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

Review 7.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

Review 8.  The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential.

Authors:  S Patricia Becerra; Vicente Notario
Journal:  Nat Rev Cancer       Date:  2013-03-14       Impact factor: 60.716

9.  Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor.

Authors:  Eugene T H Ek; Crispin R Dass; Karla G Contreras; Peter F M Choong
Journal:  Clin Exp Metastasis       Date:  2007-04-18       Impact factor: 5.150

Review 10.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.